Which is more profitable, AbbVie or UCB SA?

UCB SA keeps more of every sale as profit.

Which grows faster, AbbVie or UCB SA?

UCB SA grew its sales faster in recent years.

Which is cheaper, AbbVie or UCB SA?

UCB SA costs less for each unit of yearly profit (lower P/E).

Which has less debt, AbbVie or UCB SA?

UCB SA would need fewer years of earnings to pay off its debt.

AbbVieABBVvs

UCB SAUCB.BR

AbbVie vs UCB SA stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

UCB SA is more profitable, grows faster, is cheaper for its profits and has less debt.

Side by side

	AbbVie	UCB SA
	$521 billion	€56.5 billion
	6.9%	20.1%
	+6.0%	+12.0%
	123.4×	36.3×
	3.5 years	Net cash
	12.0%	11.2%
	3.1%	0.5%

Open AbbVie Open UCB SA

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: AbbVie vs UnitedHealth · AbbVie vs Vertex Pharmaceuticals · AbbVie vs Abbott Laboratories · AbbVie vs Amgen · UCB SA vs Johnson & Johnson · UCB SA vs Eli Lilly · UCB SA vs Roche · UCB SA vs UnitedHealth